The role and impact of Del(5q) and TP53 mutations on haematopoietic stem and progenitor cells during the progression of Myelodysplastic Syndrome to Acute Myeloid Leukaemia

The role and impact of Del(5q) and TP53 mutations on haematopoietic stem and progenitor cells during the progression of Myelodysplastic Syndrome to Acute Myeloid Leukaemia

<p>Myelodysplastic Syndromes (MDS) are a heterogeneous group of haematological malignancies characterised by ineffective haematopoiesis and dysplastic bone marrow changes. Patients frequently progress to Acute Myeloid Leukaemia and this is associated with very poor clinical outcomes. This t...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Doolittle, H
Άλλοι συγγραφείς:	Jacobsen, S
Μορφή:	Thesis
Έκδοση:	2017

Παρόμοια τεκμήρια

Characterising early human lympho-myeloid haematopoietic progenitors and their relationship with acute myeloid leukaemia stem cells
ανά: Aboukhalil, Z
Έκδοση: (2018)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
ανά: Pimjai Niparuck, κ.ά.
Έκδοση: (2021-10-01)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
ανά: Ramy Rahmé, κ.ά.
Έκδοση: (2023-04-01)

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
ανά: Daver, NG, κ.ά.
Έκδοση: (2022)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
ανά: Yuxin Wang, κ.ά.
Έκδοση: (2022-07-01)

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
ανά: Fidler, C, κ.ά.
Έκδοση: (2004)

TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
ανά: Ugo Testa, κ.ά.
Έκδοση: (2023-06-01)

P1288: UNMANIPULATED PERIPHERAL HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT IS AN EFFECTIVE CONSOLIDATIVE STRATEGY FOR HIGH-RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME
ανά: Fabio Serpenti, κ.ά.
Έκδοση: (2023-08-01)

Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
ανά: Čolović Nataša, κ.ά.
Έκδοση: (2023-01-01)

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes
ανά: Lijuan Zhang, κ.ά.
Έκδοση: (2023-12-01)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
ανά: Kathy L. McGraw, κ.ά.
Έκδοση: (2016-08-01)

Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
ανά: Laurence Lodé, κ.ά.
Έκδοση: (2018-04-01)

Identification and characterisation of the haematopoietic stem/progenitor cells at risk for leukaemia development following radiation exposure
ανά: Verbiest, T
Έκδοση: (2016)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
ανά: Y. Fang, κ.ά.
Έκδοση: (2022-06-01)

Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations
ανά: Laurence Lodé, κ.ά.
Έκδοση: (2018-01-01)

Unravelling haematopoietic stem cell dysfunction in isolated Del(5q) myelodysplastic syndromes
ανά: Stenson, L
Έκδοση: (2015)

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
ανά: Nabih Maslah, κ.ά.
Έκδοση: (2020-06-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
ανά: R Edlin, κ.ά.
Έκδοση: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
ανά: R Edlin, κ.ά.
Έκδοση: (2010-05-01)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
ανά: Nikeeta Mandhan, κ.ά.
Έκδοση: (2022-01-01)

Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia
ανά: Lu Bai, κ.ά.
Έκδοση: (2022-08-01)

Allogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors
ανά: Ahmet Emre Eskazan, κ.ά.
Έκδοση: (2018-08-01)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
ανά: Katharina T. Prochazka, κ.ά.
Έκδοση: (2019-03-01)

TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies
ανά: Marianna B. Ruzinova, κ.ά.
Έκδοση: (2019-08-01)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia
ανά: Boultwood, J, κ.ά.
Έκδοση: (2009)

Microcosting analysis of haematopoietic stem cell transplantation and chemotherapy with intermediate doses of cytarabine in the treatment of acute myeloid leukaemia
ανά: Sitânia Chiesa, κ.ά.
Έκδοση: (2024-12-01)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
ανά: Goh, Chermaine Yu Zhen
Έκδοση: (2021)

hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
ανά: Campbell, L, κ.ά.
Έκδοση: (2006)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
ανά: Matteo Molica, κ.ά.
Έκδοση: (2021-02-01)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
ανά: Pierre Bories, κ.ά.
Έκδοση: (2020-01-01)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
ανά: Pierre Bories, κ.ά.
Έκδοση: (2020-01-01)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
ανά: Haase, D, κ.ά.
Έκδοση: (2019)

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
ανά: David A. Sallman
Έκδοση: (2020-06-01)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
ανά: Shyam A. Patel, κ.ά.
Έκδοση: (2023-11-01)

Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond
ανά: Adriana Balduzzi, κ.ά.
Έκδοση: (2022-02-01)

Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.
ανά: Boultwood, J, κ.ά.
Έκδοση: (2004)

INVESTIGATION OF THE IMPACT OF THE R248Q MUTATION IN THE TP53 GENE ON THE INTERACTION OF THE P53 PROTEIN WITH THE DRUG APR-246 IN ACUTE MYELOID LEUKEMIA
ανά: LMF Bertoline, κ.ά.
Έκδοση: (2024-10-01)

Recruiting TP53 to target chronic myeloid leukemia stem cells
ανά: Steven Grant
Έκδοση: (2020-05-01)

P471: POLO-LIKE KINASE 4 INHIBITION INDUCED ANTI-LEUKAEMIC EFFECTS THROUGH HISTONE MODIFICATION IN TP53 MUTATED ACUTE MYELOID LEUKAEMIA
ανά: Wing Lam, κ.ά.
Έκδοση: (2023-08-01)

What have we learned about TP53-mutated acute myeloid leukemia?
ανά: Moazzam Shahzad, κ.ά.
Έκδοση: (2024-11-01)